Anticancer

Front 1

Alkylating agents MoA

Back 1

formation of imonium or carbonium ion intermediate, reacts with nucleophiles leading to alkylated tissue molecules
alkylation of DNA interferes w nucleic acid synthesis and function

Front 2

Alkylating agents general toxicities

Back 2

BM suppression, GI (emesis), reproductive effects

Front 3

Cyclophosphamide
(class of drugs & major SE)

Back 3

alkylating agent,
hemorrhagic cystitis (treat w/ hydration, frequent voiding, mensa)

Front 4

Procarbazine
(class of drugs & major SEs)

Back 4

non-classical alkylating agent, CNS depression, disulfiram-like effect, MAOI activity

Front 5

Cisplatin toxicities

Back 5

nephrotoxicity, ototoxicity, periph neuropathy, electrolyte disturbance, emetogenic, anaphylaxis

Front 6

Doxorubicin
main tox

Back 6

cardiomyopathy

Front 7

Methotrexate
(MoA, tox)

Back 7

inhibits DHF reductase (therefore, synthesis of thymidylate & purines)
myelosuppression, stomatitis, hepatic

Front 8

Leucovorin rescue

Back 8

antidote for excessive methotrexate

Front 9

Mechlorethamine
(class)

Back 9

alkylating agent

Front 10

Melphalan
(class)

Back 10

alkylating agent

Front 11

Cyclophosphamide
(class)

Back 11

alkylating agent

(remember: hemorrhagic cystitis!)

Front 12

Carmustine, Lomustine
(class)

Back 12

alkylating agent

Front 13

Streptozocin
(class)

Back 13

alkylating agent

Front 14

Busulfan
(class)

Back 14

alkylating agent

Front 15

Procarbazine
(class)

Back 15

nonclassical alkylating agent

(remember: disulfiram effect, MAOI effects)

Front 16

Cisplatin, Carboplatin, Oxaliplatin
(class & mech)

Back 16

platinum compounds, inhibit DNA synthesis

Front 17

Methotrexate
(class)

Back 17

folic acid analog
inhibits DHFR

Front 18

Pemetrexed
(class)

Back 18

folic acid analog
inhibits thymidylate synthase

Front 19

6-MP
(class)

Back 19

purine analog

Front 20

Fludarabine phosphate
(class)

Back 20

purine analog

Front 21

Cladribine
(class)

Back 21

purine analog

Front 22

5-FU
(class)

Back 22

purine analog, inhibits thymidylate synthase

Front 23

Cytarabine
(class)

Back 23

purine analog
S phase specific

Front 24

Gemcitabine
(class)

Back 24

purine analog
inhibits ribonucleotide reductase

Front 25

effect of TPMT

Back 25

TMPT metabolizes 6-MP & 6-TG
low activity increases toxicity

Front 26

Dactinomycin
(class & MoA)

Back 26

antitumor antibiotic
binds DNA, interferes w RNA synth

Front 27

Doxorubicin & Daunorubicin
(class & MoA)

Back 27

antitumor antibiotic
intercalate between DNA bases, inhibit DNA synth
inhibit topoisomerase II --> DNA strand breaks
forms free radicals

Front 28

Bleomycin
(class & MoA)

Back 28

antitumor antibiotic
binds to DNA --> strand breaks
generates free radicals

Front 29

Bleomycin toxicities

Back 29

pulmonary (age)
cutaneous
allergic
NOT BONE MARROW SUPPRESSION!!

Front 30

Mitomycin
(class & MoA)

Back 30

antitumor antibiotic
reduced to alkylating agent

Front 31

Vincristine & Vinblastine
(class and MoA)

Back 31

vinca alkaloids
mitotic inhibitors
bind tubulin, inhibit MT polymerization

Front 32

Vincristine tox vs. Vinblastine tox

Back 32

Vincristine: mild myelosuppression, neurotoxicity
Vinblastine: more severe myelosuppression

Front 33

Paclitaxel
(class & MoA)

Back 33

mitotic inhibitor
binds MTs, promotes polymerization

Front 34

Etoposide
(MoA)

Back 34

inhibits topoisomerase II --> DNA strand breaks

Front 35

Topotecan & Irinotecan
(MoA)

Back 35

inhibits topoisomerase I --> DNA damage

Front 36

Asparaginase
(MoA)

Back 36

catalyzes hydrolysis of asparagine to aspartic acid, depleting asparagine pool in leukemic cells

Front 37

Imantinib
(MoA & SEs)

Back 37

inhibits Bcr-Abl TK in CML
(binds ATP binding site to prevent phosphorylation)
SE: GI, edema, cramps, neutropenia, hepatotoxicity

Front 38

Cetuximab
(MoA and SEs)

Back 38

binds EGFR on cell surface
acneiform rash, low Mg2+, ILD
NO BONE MARROW SUPPRESSION!!!

Front 39

Gefitinib & Erlotinib
(MoA and SEs)

Back 39

inhibit TK domain of EGFR intracellularly
acneiform rash, ILD

Front 40

Bavacizumab
(MoA)

Back 40

binds VEGF

Front 41

Sorafenib & Sunitinib
(MoA)

Back 41

inhibits many TK receptors

Front 42

all trans retinoic acid

Back 42

induces differentiation
retinoic acid syndrome

Front 43

arsenic trioxide

Back 43

induces differentiation
QT prolongation, arrhythmias

Front 44

Bortezomib (MoA)

Back 44

proteasome inhibitor

Front 45

Hydroxyurea (MoA)

Back 45

inhibits ribonucleotide reductase (decreased DNA synth)

Front 46

Flutamide

Back 46

blocks androgen receptor

Front 47

Rituximab

Back 47

binds CD20

Front 48

Trastuzumab

Back 48

Herceptin